ChartRow logo
Data provided bySource: Twelve Data
BMRN
$58.51+0.90%
as of close, Nov 17, 2026
☾ AH $58.51 +0.90%
Share this page

BMRN SEC filings (2026)

CIK 1048477 · Pharmaceutical Preparations (SIC 2834) · incorporated in DE · fiscal year ends in December

2,729 filings on EDGAR since 1999 · 33 annual, 86 quarterly, 370 current · financial statements · earnings

Latest 10-K
Feb 26, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Nov 3, 2026
quarter to Sep 30, 2026
Latest 8-K
Nov 2, 2026
BioMarin Reports Third Quarter 2026 Financial and Operating Results
Last earnings release
Nov 2, 2026
$0.02 vs −$0.30 · ▼ 3.1%
Filings on file
2,729
since 1999, 1,790 insider forms

What happened, last 12 months#

Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.

November 2026

October 2026

September 2026

August 2026

July 2026

June 2026

May 2026

April 2026

March 2026

February 2026

January 2026

December 2025

Insider transactions#

What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.

Over the last 13 months insiders sold $4.3M in 5 sales and bought nothing on the open market; 46 other transactions (awards, exercises, tax withholding, gifts and plan purchases).

DateInsider
Sep 2, 2026Form 4Davis George EricEVP, Chief Legal OfficerSold · $1.2M · 17,557 sh
May 7, 2026Form 4Friberg Gregory REVP, Chief R&D OfficerSold · $177K · 3,281 sh
Mar 11, 2026Form 4Guyer Charles GregEVP, Chief Technical OfficerSold · $997K · 16,486 sh
Feb 26, 2026Form 4Davis George EricEVP, Chief Legal OfficerSold · $1.6M · 26,061 sh
Feb 26, 2026Form 4Friberg Gregory REVP, Chief R&D OfficerSold · $382K · 6,326 sh
Awards, exercises, withholding and plan purchases · 46 transactions
DateInsider
Sep 30, 2026Form 4Friberg Gregory REVP, Chief R&D OfficerTax withholding · $245K · 4,086 sh
Sep 10, 2026Form 4Plenge Robert MDirectorAward · $0 · 6,140 sh
Jun 2, 2026Form 4ANDERSON ELIZABETH MDirectorAward · $0 · 7,490 sh
Jun 2, 2026Form 4Bodem Barbara W.DirectorAward · $0 · 7,490 sh
Jun 2, 2026Form 4CLARK IAN TDirectorAward · $0 · 7,490 sh
Jun 2, 2026Form 4Dere Willard HDirectorAward · $0 · 7,490 sh
Jun 2, 2026Form 4Enyedy Mark JDirectorAward · $0 · 7,490 sh
Jun 2, 2026Form 4HOMBACH ROBERT J.DirectorAward · $0 · 7,490 sh
Jun 2, 2026Form 4Ho MaykinDirectorAward · $0 · 7,490 sh
Jun 2, 2026Form 4Walbert Timothy PDirectorAward · $0 · 7,490 sh
Jun 2, 2026Form 4Countouriotis AthenaDirectorAward · $0 · 7,490 sh
May 20, 2026Form 4Hubbard CristinEVP, Chief Commercial OfficerTax withholding · $116K · 2,318 sh
Mar 18, 2026Form 4Davis George EricEVP, Chief Legal OfficerTax withholding · $71K · 1,273 sh
Mar 17, 2026Form 4Hardy AlexanderChief Executive Officer · DirectorTax withholding · $238K · 4,252 sh
Mar 17, 2026Form 4Mueller BrianEVP, Chief Financial OfficerTax withholding · $119K · 2,117 sh
Mar 17, 2026Form 4Guyer Charles GregEVP, Chief Technical OfficerTax withholding · $95K · 1,693 sh
Mar 17, 2026Form 4Friberg Gregory REVP, Chief R&D OfficerTax withholding · $91K · 1,629 sh
Mar 17, 2026Form 4Hubbard CristinEVP, Chief Commercial OfficerTax withholding · $70K · 1,245 sh
Mar 16, 2026Form 4Davis George EricEVP, Chief Legal OfficerTax withholding · $420K · 7,177 sh
Mar 16, 2026Form 4Hardy AlexanderChief Executive Officer · DirectorAward · Stock Option (Right to Buy… · $0 · 89,200 sh
Mar 16, 2026Form 4Hardy AlexanderChief Executive Officer · DirectorAward · $0 · 62,440 sh
Mar 16, 2026Form 4Friberg Gregory REVP, Chief R&D OfficerAward · Stock Option (Right to Buy… · $0 · 45,600 sh
Mar 16, 2026Form 4Mueller BrianEVP, Chief Financial OfficerAward · Stock Option (Right to Buy… · $0 · 44,600 sh
Mar 16, 2026Form 4Hubbard CristinEVP, Chief Commercial OfficerAward · Stock Option (Right to Buy… · $0 · 36,680 sh
Mar 16, 2026Form 4Guyer Charles GregEVP, Chief Technical OfficerAward · Stock Option (Right to Buy… · $0 · 35,680 sh
Mar 16, 2026Form 4Davis George EricEVP, Chief Legal OfficerAward · Stock Option (Right to Buy… · $0 · 34,690 sh
Mar 16, 2026Form 4Friberg Gregory REVP, Chief R&D OfficerAward · $0 · 19,150 sh
Mar 16, 2026Form 4Mueller BrianEVP, Chief Financial OfficerAward · $0 · 18,740 sh
Mar 16, 2026Form 4Hubbard CristinEVP, Chief Commercial OfficerAward · $0 · 15,410 sh
Mar 16, 2026Form 4Guyer Charles GregEVP, Chief Technical OfficerAward · $0 · 14,990 sh
Mar 16, 2026Form 4Davis George EricEVP, Chief Legal OfficerAward · $0 · 14,570 sh
Mar 13, 2026Form 4Mueller BrianEVP, Chief Financial OfficerTax withholding · $582K · 9,945 sh
Mar 13, 2026Form 4Guyer Charles GregEVP, Chief Technical OfficerTax withholding · $533K · 9,109 sh
Mar 13, 2026Form 4Hardy AlexanderChief Executive Officer · DirectorTax withholding · $172K · 2,941 sh
Feb 25, 2026Form 4Mueller BrianEVP, Chief Financial OfficerAward · $0 · 16,482 sh
Feb 25, 2026Form 4Davis George EricEVP, Chief Legal OfficerAward · $0 · 15,224 sh
Feb 25, 2026Form 4Guyer Charles GregEVP, Chief Technical OfficerAward · $0 · 15,222 sh
Jan 20, 2026Form 4Ramchandani Rashmi VirendraVP, Chief Accounting OfficerAward · $0 · 25,610 sh
Jan 20, 2026Form 4Ramchandani Rashmi VirendraVP, Chief Accounting OfficerAward · Stock Option (Right to Buy… · $0 · 18,220 sh
Dec 30, 2025Form 4MEIER RICHARD ADirectorGift · $0 · 500 sh
Oct 31, 2025Form 4Friberg Gregory REVP, Chief R&D OfficerAward · $18K · 398 sh
Oct 31, 2025Form 4Hubbard CristinEVP, Chief Commercial OfficerAward · $3,643 · 80 sh
Oct 31, 2025Form 4Guyer Charles GregEVP, Chief Technical OfficerAward · $2,823 · 62 sh
Apr 30, 2025Form 4Davis George EricEVP, Chief Legal OfficerAward · $20K · 375 sh
Apr 30, 2025Form 4Mueller BrianEVP, Chief Financial OfficerAward · $20K · 375 sh
Apr 30, 2025Form 4Guyer Charles GregEVP, Chief Technical OfficerAward · $17K · 317 sh

Reports and proxy statements#

Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.

2026 · 27 filings
FiledWhat it is
Nov 3, 202610-QQuarterly report, Q3 2026 — revenue $1.02B (+32% y/y), net income −$122.8M, EPS −$0.63
Nov 2, 20268-KEarnings release — EPS $0.02 vs −$0.30 est. (+106.7%); revenue $1.02B (+32% y/y) 3.1%
Oct 6, 20268-KResults of operations
Sep 30, 20268-KMaterial definitive agreement
Sep 15, 20268-KOther events
Sep 14, 20268-KDirectors or officers; compensation
Sep 1, 20268-KOther events
Aug 31, 20268-KBioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South KoreaMaterial definitive agreement; Regulation FD disclosure
Aug 18, 20268-KBioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin’s PipelineMaterial definitive agreement; Regulation FD disclosure
Aug 6, 202610-QQuarterly report, Q2 2026 — revenue $989.7M (+20% y/y), net income $44.8M, EPS $0.23
Aug 6, 20268-KEarnings release — EPS $0.90 vs $0.79 est. (+13.9%); revenue $989.7M (+20% y/y) 3.8%
Jul 13, 20268-K/AOther events
Jun 4, 20268-KDirectors or officers; compensation; Shareholder vote results
May 5, 202610-QQuarterly report, Q1 2026 — revenue $766.2M (+3% y/y), net income $105.5M, EPS $0.54
May 4, 20268-KEarnings release — EPS $0.58 vs $0.78 est. (−25.6%); revenue $766.2M (+3% y/y) 4.0%
Apr 27, 20268-KBioMarin Completes Acquisition of Amicus TherapeuticsMaterial definitive agreement; Completion of an acquisition or disposition; New financial obligation; Regulation FD disclosure
Apr 23, 20268-KOther events
Apr 21, 2026ARSAnnual report to shareholders
Apr 21, 2026DEFA14AAdditional proxy materials
Apr 21, 2026DEF 14AProxy statement
Mar 16, 20268-KOther events
Feb 26, 202610-KAnnual report, FY2025 — revenue $3.22B (+13% y/y), net income $348.9M, EPS $1.80
Feb 23, 20268-KEarnings release — EPS $0.28 vs $0.07 est. (+300.0%); revenue $874.6M (+17% y/y) 0.5%
Feb 12, 20268-KBioMarin Announces Closing of Private Offering of Senior NotesMaterial definitive agreement; New financial obligation; Regulation FD disclosure
Jan 29, 20268-KBioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan FacilityRegulation FD disclosure
Jan 26, 20268-KBioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan FacilityResults of operations; Regulation FD disclosure; Other events
Jan 12, 20268-KResults of operations
2025 · 21 filings
FiledWhat it is
Dec 22, 20258-KOther events
Dec 19, 20258-KBioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial OutlookMaterial definitive agreement; Regulation FD disclosure
Dec 17, 20258-KDirectors or officers; compensation
Oct 28, 202510-QQuarterly report, Q3 2025 — revenue $776.1M (+4% y/y), net income −$30.7M, EPS −$0.16
Oct 27, 20258-KEarnings release — EPS −$0.08 vs $0.82 est. (−109.8%); revenue $776.1M (+4% y/y) 1.6%
Oct 7, 20258-KResults of operations
Aug 11, 20258-KDirectors or officers; compensation
Aug 5, 202510-QQuarterly report, Q2 2025 — revenue $825.4M (+16% y/y), net income $240.5M, EPS $1.23
Aug 4, 20258-KEarnings release — EPS $1.25 vs $0.80 est. (+56.3%); revenue $825.4M (+16% y/y) 2.7%
Aug 1, 20258-KDirectors or officers; compensation
May 22, 20258-KDirectors or officers; compensation; Shareholder vote results
May 16, 20258-KMaterial definitive agreement; Regulation FD disclosure
May 2, 202510-QQuarterly report, Q1 2025 — revenue $745.1M (+15% y/y), net income $185.7M, EPS $0.95
May 1, 20258-KEarnings release — EPS $0.98 vs $0.73 est. (+34.3%); revenue $745.1M (+15% y/y) 1.1%
Apr 8, 2025ARSAnnual report to shareholders
Apr 8, 2025DEFA14AAdditional proxy materials
Apr 8, 2025DEF 14AProxy statement
Mar 3, 20258-KChange to security holders' rights; Charter, bylaws or fiscal-year change
Feb 24, 20258-KDirectors or officers; compensation
Feb 24, 202510-KAnnual report, FY2024 — revenue $2.85B (+18% y/y), net income $426.9M, EPS $2.21
Feb 19, 20258-KEarnings release — EPS $0.72 vs $0.55 est. (+30.9%); revenue $747.3M (+16% y/y) 4.8%
2024 · 19 filings
FiledWhat it is
Oct 31, 202410-QQuarterly report, Q3 2024 — revenue $745.7M (+28% y/y), net income $106.1M, EPS $0.55
Oct 29, 20248-KEarnings release — EPS $0.74 vs $0.57 est. (+29.8%); revenue $745.7M (+28% y/y) 4.6%
Sep 24, 20248-KRegulation FD disclosure
Sep 4, 20248-KMaterial definitive agreement; New financial obligation
Aug 28, 20248-KExit or disposal costs
Aug 22, 20248-KDirectors or officers; compensation
Aug 5, 202410-QQuarterly report, Q2 2024 — revenue $712.0M (+20% y/y), net income $107.2M, EPS $0.55
Aug 5, 20248-KEarnings release — EPS $0.77 vs $0.38 est. (+102.6%); revenue $712.0M (+20% y/y) 8.0%
May 24, 20248-KShareholder vote results
May 14, 20248-KExit or disposal costs
Apr 26, 202410-QQuarterly report, Q1 2024 — revenue $648.8M (+9% y/y), net income $88.7M, EPS $0.46
Apr 24, 20248-KEarnings release — EPS $0.49 vs $0.37 est. (+32.4%); revenue $648.8M (+9% y/y) 9.9%
Apr 23, 20248-KOther events
Apr 9, 2024ARSAnnual report to shareholders
Apr 9, 2024DEFA14AAdditional proxy materials
Apr 9, 2024DEF 14AProxy statement
Feb 26, 202410-KAnnual report, FY2023 — revenue $2.42B (+15% y/y), net income $167.6M, EPS $0.87
Feb 22, 20248-KEarnings release — EPS $0.26 vs $0.24 est. (+8.3%); revenue $646.2M (+20% y/y) 1.4%
Jan 11, 20248-KDirectors or officers; compensation
2023 · 15 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
FiledWhat it is
Nov 2, 202310-QQuarterly report, Q3 2023 — revenue $581.3M (+15% y/y), net income $40.4M, EPS $0.21
Aug 2, 202310-QQuarterly report, Q2 2023 — revenue $595.3M (+12% y/y), net income $56.0M, EPS $0.29
Apr 28, 202310-QQuarterly report, Q1 2023 — revenue $596.4M (+15% y/y), net income $50.9M, EPS $0.27
Apr 11, 2023ARSAnnual report to shareholders
Apr 11, 2023DEFA14AAdditional proxy materials
Apr 11, 2023DEF 14AProxy statement
Feb 27, 202310-KAnnual report, FY2022 — revenue $2.10B (+14% y/y), net income $141.6M, EPS $0.75

8 current reports (8-K) not listed; the year is on EDGAR.

2022 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
FiledWhat it is
Oct 28, 202210-QQuarterly report, Q3 2022 — revenue $505.3M (+24% y/y), net income −$6.7M, EPS −$0.04
Aug 4, 202210-QQuarterly report, Q2 2022 — revenue $533.8M (+6% y/y), net income $27.7M, EPS $0.15
Apr 29, 202210-QQuarterly report, Q1 2022 — revenue $519.4M (+7% y/y), net income $120.8M, EPS $0.63
Apr 12, 2022DEFA14AAdditional proxy materials
Apr 12, 2022DEF 14AProxy statement
Feb 25, 202210-KAnnual report, FY2021 — revenue $1.85B (−1% y/y), net income −$64.1M, EPS −$0.35

10 current reports (8-K) not listed; the year is on EDGAR.

2021 · 16 filings — 9 × 8-K, 3 × 10-Q, 2 × DEFA14A and 2 other forms
FiledWhat it is
Oct 29, 202110-QQuarterly report, Q3 2021 — revenue $408.7M (−14% y/y), net income −$36.5M, EPS −$0.20
Jul 30, 202110-QQuarterly report, Q2 2021 — revenue $501.7M (+17% y/y), net income $12.9M, EPS $0.07
May 17, 2021DEFA14AAdditional proxy materials
Apr 30, 202110-QQuarterly report, Q1 2021 — revenue $486.0M (−3% y/y), net income $17.4M, EPS $0.09
Apr 13, 2021DEFA14AAdditional proxy materials
Apr 13, 2021DEF 14AProxy statement
Feb 26, 202110-KAnnual report, FY2020 — revenue $1.86B (+9% y/y), net income $854.0M, EPS $4.50

9 current reports (8-K) not listed; the year is on EDGAR.

2020 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
FiledWhat it is
Nov 6, 202010-QQuarterly report, Q3 2020 — revenue $476.8M (+3% y/y), net income $784.8M, EPS $4.01
Aug 5, 202010-QQuarterly report, Q2 2020 — revenue $429.5M (+11% y/y), net income −$29.2M, EPS −$0.16
May 1, 202010-QQuarterly report, Q1 2020 — revenue $502.1M (+25% y/y), net income $81.4M, EPS $0.44
Apr 14, 2020DEFA14AAdditional proxy materials
Apr 14, 2020DEF 14AProxy statement
Feb 27, 202010-KAnnual report, FY2019 — revenue $1.70B (+14% y/y), net income −$23.8M, EPS −$0.13

12 current reports (8-K) not listed; the year is on EDGAR.

2019 · 14 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
FiledWhat it is
Nov 4, 201910-Q/AQuarterly report, amended
Oct 29, 201910-QQuarterly report
Aug 2, 201910-QQuarterly report, Q2 2019 — revenue $387.8M (+4% y/y), net income −$37.4M, EPS −$0.21
Apr 29, 201910-QQuarterly report, Q1 2019 — revenue $400.7M (+7% y/y), net income −$56.5M, EPS −$0.32
Apr 23, 2019DEFA14AAdditional proxy materials
Apr 23, 2019DEF 14AProxy statement
Feb 28, 201910-KAnnual report, FY2018 — revenue $1.49B (+14% y/y), net income −$77.2M, EPS −$0.44

7 current reports (8-K) not listed; the year is on EDGAR.

2018 · 13 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
FiledWhat it is
Oct 26, 201810-QQuarterly report, Q3 2018 — revenue $391.7M (+17% y/y), net income −$12.6M, EPS −$0.07
Aug 3, 201810-QQuarterly report, Q2 2018 — revenue $372.8M (+17% y/y), net income −$16.8M
Apr 27, 201810-QQuarterly report, Q1 2018 — revenue $373.4M (+23% y/y), net income −$44.1M, EPS −$0.26
Apr 24, 2018DEFA14AAdditional proxy materials
Apr 24, 2018DEF 14AProxy statement
Feb 26, 201810-KAnnual report, FY2017 — revenue $1.31B (+18% y/y), net income −$117.0M, EPS −$0.67

7 current reports (8-K) not listed; the year is on EDGAR.

2017 · 17 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
FiledWhat it is
Nov 13, 201710-Q/AQuarterly report, amended
Oct 31, 201710-QQuarterly report, Q3 2017 — revenue $334.1M (+19% y/y), net income −$12.5M, EPS −$0.07
Aug 2, 201710-QQuarterly report, Q2 2017 — revenue $317.4M (+6% y/y), net income −$36.8M
May 4, 201710-QQuarterly report, Q1 2017 — revenue $303.7M (+28% y/y), net income −$16.3M, EPS −$0.09
Apr 25, 2017DEFA14AAdditional proxy materials
Apr 25, 2017DEF 14AProxy statement
Apr 11, 2017PRE 14APreliminary proxy statement
Feb 27, 201710-KAnnual report, FY2016 — revenue $1.12B (+26% y/y), net income −$630.2M, EPS −$3.81

9 current reports (8-K) not listed; the year is on EDGAR.

2016 · 21 filings — 13 × 8-K, 3 × 10-Q, 2 × 8-K/A and 3 other forms

Counted, not listed; the year is on EDGAR.

2015 · 25 filings — 17 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2014 · 24 filings — 15 × 8-K, 3 × 10-Q, 2 × 8-K/A and 4 other forms

Counted, not listed; the year is on EDGAR.

2013 · 22 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2012 · 20 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2011 · 16 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2010 · 23 filings — 13 × 8-K, 3 × 10-Q, 2 × 8-K/A and 5 other forms

Counted, not listed; the year is on EDGAR.

2009 · 19 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2008 · 14 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2007 · 17 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2006 · 23 filings — 17 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2005 · 42 filings — 22 × 8-K, 3 × 10-Q, 2 × 10-K/A and 9 other forms

Counted, not listed; the year is on EDGAR.

2004 · 29 filings — 21 × 8-K, 3 × 10-Q, 2 × 8-K/A and 3 other forms

Counted, not listed; the year is on EDGAR.

2003 · 31 filings — 23 × 8-K, 3 × 10-Q, 2 × 8-K/A and 3 other forms

Counted, not listed; the year is on EDGAR.

2002 · 39 filings — 25 × 8-K, 3 × 10-Q, 3 × 8-K/A and 6 other forms

Counted, not listed; the year is on EDGAR.

2001 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2000 · 6 filings — 3 × 10-Q, 1 × 10-K, 1 × 8-K and 1 other form

Counted, not listed; the year is on EDGAR.

1999 · 2 filings — 2 × 10-Q

Counted, not listed; the year is on EDGAR.

Insider, ownership and other filings#

Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.

2026 · 48 filings — 30 × 4, 6 × 5, 5 × 144 and 4 other forms
FiledWhat it is
Nov 4, 2026SCHEDULE 13G/AOther filings
Oct 1, 20264Insider transaction (Form 4)
Sep 14, 20264Insider transaction (Form 4)
Sep 14, 20263Initial insider holdings (Form 3)
Sep 3, 20264Insider transaction (Form 4)
Sep 2, 2026144Notice of proposed sale (Form 144)
Aug 6, 2026S-8Employee stock plan registration
Jun 4, 20264Insider transaction (Form 4)
Jun 4, 20264Insider transaction (Form 4)
Jun 4, 20264Insider transaction (Form 4)
Jun 4, 20264Insider transaction (Form 4)
Jun 4, 20264Insider transaction (Form 4)
Jun 4, 20264Insider transaction (Form 4)
Jun 4, 20264Insider transaction (Form 4)
Jun 4, 20264Insider transaction (Form 4)
Jun 4, 20264Insider transaction (Form 4)
May 21, 20264Insider transaction (Form 4)
May 11, 20264Insider transaction (Form 4)
May 7, 2026144Notice of proposed sale (Form 144)
Apr 29, 2026SCHEDULE 13GOther filings
Mar 26, 2026SCHEDULE 13G/AOther filings
Mar 19, 20264Insider transaction (Form 4)
Mar 19, 20264Insider transaction (Form 4)
Mar 19, 20264Insider transaction (Form 4)
Mar 19, 20264Insider transaction (Form 4)

The newest 25 of 48 shown; the full year is on EDGAR.

2025 · 55 filings — 30 × 4, 6 × SCHEDULE 13G/A, 5 × 144 and 7 other forms
FiledWhat it is
Dec 2, 20254Insider transaction (Form 4)
Nov 14, 2025SCHEDULE 13G/AOther filings
Oct 2, 20254Insider transaction (Form 4)
Aug 14, 2025SCHEDULE 13G/AOther filings
Aug 14, 2025SCHEDULE 13G/AOther filings
Aug 5, 20254Insider transaction (Form 4)
Aug 5, 20253Initial insider holdings (Form 3)
Aug 5, 2025S-8Employee stock plan registration
Jul 1, 2025SC TO-T/ABeneficial ownership
Jun 17, 2025SC TO-T/ABeneficial ownership
Jun 13, 2025CORRESPLetter to the SEC
Jun 13, 2025SC TO-T/ABeneficial ownership
Jun 4, 2025SC TO-T/ABeneficial ownership
Jun 2, 2025SC TO-TBeneficial ownership
May 22, 20254Insider transaction (Form 4)
May 22, 20254Insider transaction (Form 4)
May 22, 20254Insider transaction (Form 4)
May 22, 20254Insider transaction (Form 4)
May 22, 20254Insider transaction (Form 4)
May 22, 20254Insider transaction (Form 4)
May 22, 20254Insider transaction (Form 4)
May 22, 20254Insider transaction (Form 4)
May 22, 20254Insider transaction (Form 4)
May 22, 20254Insider transaction (Form 4)
May 20, 20254Insider transaction (Form 4)

The newest 25 of 55 shown; the full year is on EDGAR.

2024 · 92 filings — 51 × 4, 26 × 144, 6 × SC 13G/A and 5 other forms
FiledWhat it is
Dec 3, 20244Insider transaction (Form 4)
Nov 14, 20244Insider transaction (Form 4)
Nov 12, 2024144Notice of proposed sale (Form 144)
Oct 3, 2024UPLOADLetter from the SEC staff
Oct 1, 20244Insider transaction (Form 4)
Oct 1, 20243Initial insider holdings (Form 3)
Sep 30, 2024SC 13GPassive holder above 5% (Schedule 13G)
Sep 17, 20244Insider transaction (Form 4)
Sep 16, 2024CORRESPLetter to the SEC
Sep 2, 2024UPLOADLetter from the SEC staff
Aug 15, 20244Insider transaction (Form 4)
Aug 13, 2024144Notice of proposed sale (Form 144)
Jul 10, 2024SC 13G/APassive holder above 5% (Schedule 13G), amended
Jul 8, 2024SC 13G/APassive holder above 5% (Schedule 13G), amended
Jul 1, 20244Insider transaction (Form 4)
Jun 4, 20244Insider transaction (Form 4)
Jun 4, 20244Insider transaction (Form 4)
Jun 4, 2024144Notice of proposed sale (Form 144)
May 31, 20244Insider transaction (Form 4)
May 31, 2024144Notice of proposed sale (Form 144)
May 30, 20244Insider transaction (Form 4)
May 30, 2024144Notice of proposed sale (Form 144)
May 30, 2024144Notice of proposed sale (Form 144)
May 30, 2024144Notice of proposed sale (Form 144)
May 29, 2024144Notice of proposed sale (Form 144)

The newest 25 of 92 shown; the full year is on EDGAR.

2023 · 86 filings — 54 × 4, 16 × 144, 5 × SC 13G/A and 5 other forms

Counted, not listed; the year is on EDGAR.

2022 · 75 filings — 61 × 4, 5 × SC 13G/A, 2 × 3 and 5 other forms

Counted, not listed; the year is on EDGAR.

2021 · 65 filings — 54 × 4, 5 × SC 13G/A, 2 × 5 and 4 other forms

Counted, not listed; the year is on EDGAR.

2020 · 67 filings — 57 × 4, 7 × SC 13G/A, 2 × 3 and 1 other form

Counted, not listed; the year is on EDGAR.

2019 · 90 filings — 80 × 4, 6 × SC 13G/A, 1 × 3 and 3 other forms

Counted, not listed; the year is on EDGAR.

2018 · 135 filings — 107 × 4, 13 × 4/A, 8 × SC 13G/A and 3 other forms

Counted, not listed; the year is on EDGAR.

2017 · 118 filings — 89 × 4, 5 × 4/A, 5 × SC 13G/A and 11 other forms

Counted, not listed; the year is on EDGAR.

2016 · 114 filings — 92 × 4, 5 × 5, 4 × SC 13G/A and 7 other forms

Counted, not listed; the year is on EDGAR.

2015 · 100 filings — 75 × 4, 7 × SC 13G/A, 4 × SC TO-T/A and 9 other forms

Counted, not listed; the year is on EDGAR.

2014 · 111 filings — 83 × 4, 7 × SC TO-C, 4 × 5 and 11 other forms

Counted, not listed; the year is on EDGAR.

2013 · 131 filings — 105 × 4, 8 × 5, 5 × SC 13G/A and 9 other forms

Counted, not listed; the year is on EDGAR.

2012 · 132 filings — 106 × 4, 6 × SC 13G/A, 3 × 3 and 11 other forms

Counted, not listed; the year is on EDGAR.

2011 · 97 filings — 87 × 4, 6 × SC 13G/A, 1 × 3 and 3 other forms

Counted, not listed; the year is on EDGAR.

2010 · 100 filings — 76 × 4, 4 × 4/A, 4 × CT ORDER and 7 other forms

Counted, not listed; the year is on EDGAR.

2009 · 74 filings — 53 × 4, 7 × SC 13G/A, 3 × 5 and 6 other forms

Counted, not listed; the year is on EDGAR.

2008 · 138 filings — 115 × 4, 8 × SC 13G/A, 5 × CORRESP and 6 other forms

Counted, not listed; the year is on EDGAR.

2007 · 81 filings — 66 × 4, 5 × SC 13G/A, 2 × 4/A and 6 other forms

Counted, not listed; the year is on EDGAR.

2006 · 69 filings — 51 × 4, 5 × SC 13G/A, 4 × 424B5 and 6 other forms

Counted, not listed; the year is on EDGAR.

2005 · 64 filings — 31 × 4, 5 × 3, 5 × SC 13G/A and 12 other forms

Counted, not listed; the year is on EDGAR.

2004 · 47 filings — 26 × 4, 6 × SC 13G, 5 × 424B3 and 5 other forms

Counted, not listed; the year is on EDGAR.

2003 · 36 filings — 19 × 4, 3 × 424B2, 3 × SC 13G/A and 8 other forms

Counted, not listed; the year is on EDGAR.

2002 · 8 filings — 2 × S-3, 2 × S-3/A, 1 × 424B3 and 3 other forms

Counted, not listed; the year is on EDGAR.

2001 · 19 filings — 5 × 424B2, 5 × S-3/A, 3 × S-3 and 5 other forms

Counted, not listed; the year is on EDGAR.

2000 · 3 filings — 2 × SC 13G, 1 × S-3

Counted, not listed; the year is on EDGAR.

1999 · 9 filings — 4 × S-1/A, 1 × 424B4, 1 × 8-A12G and 3 other forms

Counted, not listed; the year is on EDGAR.

About this data#

BioMarin Pharmaceutical Inc. (BMRN) has 2,729 filings on EDGAR going back to 1999: 33 annual reports, 86 quarterly reports and 370 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 26, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Nov 2, 2026, furnished a press release headed “BioMarin Reports Third Quarter 2026 Financial and Operating Results”. Over the last 13 months insiders sold $4.3M in 5 sales and bought nothing on the open market; 46 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.

Every row is a filing EDGAR lists for the registrants that have been BioMarin Pharmaceutical Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.

FAQ#

Where can I read BMRN's latest 10-K?
BMRN's latest annual report, a 10-K, was filed on Feb 26, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
When did BMRN last file an 8-K?
On Nov 2, 2026 it furnished a press release headed “BioMarin Reports Third Quarter 2026 Financial and Operating Results”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Nov 2, 2026.
Are BMRN insiders buying or selling?
Over the last 13 months insiders sold $4.3M in 5 sales and bought nothing on the open market; 46 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Davis George Eric (EVP, Chief Legal Officer) sold 17,557 shares on Sep 2, 2026 for $1.2M. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
How many SEC filings has BMRN made?
2,729 filings are on EDGAR under the registrant records that have been BioMarin Pharmaceutical Inc., going back to 1999; 1,790 of them are insider ownership forms (Forms 3, 4, 5 and 144).